Interestingly, the low mutation rate of ELF3 in lung cancer has allowed it to elude sequencing-based screens of recurrently altered oncogenes; the high frequency of alternative DNA-level disruptions in upwards of 80% of LUAD underscores the importance of interrogating multiple ‘omics' levels. This evidence concerns the gene ELF3 and lung carcinoma.